Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Eisai Report Five-Year Leqembi Data Showing Sustained Alzheimer's Benefit

(RTTNews) - BioArctic AB's partner Eisai Co., Ltd. (4523.T) presented long-term data from the Phase 3 Clarity AD trial showing that continuous treatment with LEQEMBI (lecanemab-irmb) provided sustained benefits in patients with early Alzheimer's disease.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Other reports of this story

Every outlet that reported this, and when →

Read the original at nasdaq.com →

More in Health & Medicine

More from Tuesday 17 November →